Cardior Pharmaceuticals PCR kit receives CE marking

2019 09 05 21 14 7857 Heart Pulmonary Trunk 400

Cardior Pharmaceuticals said Thursday that it has received CE marking for its CardiorHealth miR-132 PCR kit.

The kit measures circulating microRNA-132 in the blood of patients who have received the company's oligonucleuotide-based miR-132 inhibitor, CDR132L.

Cardior is conducting a Phase 2 clinical study, HF-REVERT, to evaluate the safety and efficacy of CDR132L in patients with heart failure and reduced left ventricular ejection fraction after a myocardial infarction.

By selectively blocking aberrant miR-132 levels, CDR132L has the potential to reverse cellular pathology and restore normal cardiac function, the firm said.

The CardiorHealth miR-132 PCR kit is designed to monitor the treatment with a noncoding RNA-based therapeutic platform, it added.

Page 1 of 22
Next Page